In a recent analysis update, B. Riley's financial expert Mayank Mamtani has revised his price target for Agenus (AGEN, Financial), reducing it to $8 from a previous target of $11. Despite this adjustment, the analyst maintains a Buy rating on the biotechnology company's shares.
The revision follows a review of the company's performance and financial disclosures from its latest earnings report last month. While the adjustment reflects some tempered expectations, the Buy rating indicates continued confidence in Agenus's potential for growth in the biopharmaceutical sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Agenus Inc (AGEN, Financial) is $7.00 with a high estimate of $11.00 and a low estimate of $3.00. The average target implies an upside of 227.81% from the current price of $2.14. More detailed estimate data can be found on the Agenus Inc (AGEN) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Agenus Inc's (AGEN, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Agenus Inc (AGEN, Financial) in one year is $3.86, suggesting a upside of 80.76% from the current price of $2.1354. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Agenus Inc (AGEN) Summary page.
